Comparison of different treatment modalities for disc edema secondary to ischemia of optic disc

Comparative study between oral steroids, intravitreal triamcinolone and intravitreal bevacizumab in Non Arteritic Anterior Ischemic Optic Neuropathy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/12/039042

Enrollment

Registered

2021-12-30

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H470- Disorders of optic nerve, not elsewhere classified

Interventions

Intervention1: Treatment of Non Arteritic Anterior Ischemic Optic Neuropathy: Treating Non Arteritic Anterior Ischemic Optic Neuropathy with different treatment modalities, involving 3 drugs and compa

Eligibility

Inclusion criteria

Inclusion criteria: All diagnosed cases of NA- AION with a history of sudden visual loss and an absence of other ocular, systemic or neurological diseases that might influence or explain the patientâ??s visual symptoms, with, Optic disc edema (ODE) at onset and must still be present ( for referred cases) for inclusion in this study, with, Optic disc related Visual field defects ( in cases where VF analysis is feasible) The patient must not have had any treatment for NA-AION prior to our evaluation,

Exclusion criteria

Exclusion criteria: Patients who had any retinal or optic nerve lesion (Amblyopia, Glaucoma/ Vascular diseases/ Uveitis) or any other factor (e.g., cataract) which could influence the visual status. NA-AION patients with only background diabetic retinopathy were included, but those who had active neovascularization, vitreous hemorrhages, traction detachment, DME or other complications influencing the visual acuity or fields are excluded. Patients who had a diagnosis of glaucoma and visual field loss are excluded; however, those with history of elevated intraocular pressure and on ocular hypotensive therapy, with a documented normal field prior to the onset of NA-AION, are included. Patients with a follow-up of less than 3 months are excluded.

Design outcomes

Primary

Measure	Time frame
The improvement in the visual acuity and mean nerve fibre layer thickness post treatment.Timepoint: Primary outcome measures will be recorded at one week at one month at three weeks months post treatment	—

Secondary

Measure	Time frame
The improvement in the mean deviation on Humphrey visual field analysisTimepoint: At first visit at one week at one month at 3 months	—

Countries

India

Contacts

Public ContactDr Ashok Kanakamedala

Sankara Eye Hospital, Guntur

dr.ashok83@gmail.com7799444282

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026